Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6070 and ifinatamab deruxtecan in relapsed/refractory extensive-stage small cell lung cancer
2024-517926-25-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of gocatamig, ifinatamab deruxtecan and durvalumab in small cell lung cancer (SCLC) (5 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience an adverse event, Number of participants who experience one or more dose-limiting toxicities and 2 more. Planned start Mar 2025; status: authorised.
02
Drugs
gocatamigifinatamab deruxtecandurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-517926-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517926-25-00.